Marty Tenenbaum to Speak at ALCF Lung Cancer Living Room, April 22

Cancer Commons founder Marty Tenenbaum will be the guest speaker at the Bonnie J. Addario Lung Cancer Foundation’s (ALCF) monthly Lung Cancer Living Room event on Tuesday, April 22. Marty’s own cancer diagnosis and treatment journey inspired his current mission: to make sure critical information is shared and gets to the patients who need it. By collecting data from thousands of patient-donated lung cancer stories, Cancer Commons can begin to show patients and doctors patterns in treatment choices, side effects, quality of life, outcomes, and more.

The ALCF, one of our partner organizations, works directly with individual lung cancer patients to ensure they each receive the best possible care. The Lung Cancer Living Room is a monthly in-person and online support group event that informs patients about lung cancer.

Click here for more information, including how to attend in person (in San Carlos, CA) or online. Click here to read the description of Marty’s upcoming event.

Big Data Meets Cancer: Netflix CPO Neil Hunt Explains Why Cancer Commons Matters in TEDx Talk

Late last year, Netflix Chief Product Officer and Cancer Commons supporter Neil Hunt gave a talk at TEDxBeaconStreet. He believes that big data analysis outside of traditional clinical trials can help identify personalized treatments for individual patients that can significantly improve their chances of survival. As Hunt explains, Cancer Commons is an exciting embodiment of this new approach to life-saving cancer research. Watch the video:

NPR Covers Cancer Commons

CommonHealth, a blog affiliated with Boston’s NPR news station WBUR, recently posted an interview with Cancer Commons founder Marty Tenenbaum. Reporter Rachel Zimmerman caught up with Marty after a talk he gave at MIT in Cambridge. Marty told her his personal story, explained why Cancer Commons is collecting stories from other patients, and placed Cancer Commons’ efforts in the context of rapidly evolving understanding of the science behind cancer.

A quote from Marty: ” ‘We’re patient focused and science based; Our mission is to aggregate and analyze data, to provide patients with the best information — up-to-the-moment, personalized, and actionable to help them make informed decisions…like a Lonely Planet guide to cancer.’ ”

Read the full post here:

Video: Marty Tenenbaum Speaks at Microsoft Research

Cancer Commons founder Marty Tenenbaum, PhD, recently visited Microsoft’s Richmond, CA, office to give a presentation entitled “How to Beat Cancer.”

Because of “a convergence of recent developments in genomics, big data informatics, social networks, and personalized medicine that is transforming the landscape of cancer research and treatment,” Marty says, “we are now on the threshold of being able to give each individual the knowledge, resources, and tools needed to successfully treat the one disease that matters most to them.”

Watch the complete presentation at the Microsoft Research site.

Nature Reviews Clinical Oncology Publishes Paper by Marty Tenenbaum

Today the journal Nature Reviews Clinical Oncology published a paper written by Cancer Commons founder Marty Tenenbaum and co-author Jeff Shrager. The piece discusses the concept of Rapid Learning Precision Oncology. In this approach, every patient receives the best available treatment for them, based on the specifics of their diagnosis. Then the outcomes (e.g., tumor shrinkage, side effects, quality of life, etc.) are used to support and refine the treatment model on which patients’ treatment decisions are based. Tenenbaum and Shrager review the Rapid Learning Precision Oncology approach and the many challenges to its implementation.

Read the article: Rapid learning for precision oncology. Nature Reviews Clinical Oncology. Jan 21, 2014. doi: 10.1038/nrclinonc.2013.244

Please contact us if you are interested in a pdf of the paper.

Cancer Commons Partners with the Melanoma Research Foundation to Launch Online Patient Registry

Today Cancer Commons and the Melanoma Research Foundation announce an online patient registry to advance research for a cure.

For Immediate Release: January 17, 2014


The Melanoma Research Foundation and Cancer Commons partner to launch online patient registry to advance research for a cure

Donate Your Data (DYD) is the first platform to collect open-access information that will be made available to patients, physicians and researchers

Washington, DC, and Palo Alto, California, January 17, 2014 – The Melanoma Research Foundation (MRF) and Cancer Commons today announce the launch of the Donate Your Data (DYD) Program, an online registry for melanoma patients and survivors. DYD encourages patients to anonymously share their cancer experiences to advance research and, in return, inform their own clinical care.

Melanoma is one of the fastest growing cancers. With a 1 in 50 lifetime risk of developing melanoma, nearly 77,000 Americans were expected to be diagnosed with the disease in 2013, resulting in over 9,400 deaths.

Through DYD, each melanoma patient records and updates personal disease characteristics in a private, secure online profile. Entries capture stage, treatments, molecular test results, side effects, and treatment responses. All data will be made freely available in de-identified form, giving doctors, researchers, and patients themselves an unprecedented resource to determine the best approaches to melanoma care, according to each patient’s unique clinical history.

“DYD aims to collect data from at least 10% of the approximately 1 million melanoma patients and survivors in the U.S., and even more worldwide,” says Shelby Moneer, Education Program Manager at the MRF. “Our partnership with Cancer Commons is an exciting new facet of our commitment to providing patient resources and supporting research into effective treatments and eventually, a cure for this disease.”

Continue reading…

Marty Tenenbaum to Lead Panel Discussion at 2014 Personalized Medicine World Conference

Cancer Commons founder Marty Tenenbaum will lead a panel discussion at the 2014 Personalized Medicine World Conference (PMWC) on Jan 27. The discussion, entitled, “PM in Oncology Today: Making It Work for Patients, Clinicians, Researchers, and Industry,” will also feature George Demetri of Dana-Farber/Harvard Cancer Center, Vincent A. Miller of Foundation Medicine, lung cancer survivor Neil Schiffman, and Edgar Staren of CTCA Medicine and Science. Their diverse perspectives will ignite insightful discussion regarding the current use and future promise of personalized medicine in cancer.

The 6th annual PMWC conference in Silicon Valley runs Jan 27–28. It brings together leaders from multiple sectors—including business, government, healthcare-delivery, research and technology—to learn from each other and further the field of personalized medicine. Dr. Tenenbaum’s panel discussion is at 11 am on the main-stage. General registration is available through Jan 24.

Marty Tenenbaum to Speak at Monte Jade Forum on Personalized Medicine

Cancer Commons founder Marty Tenenbaum, PhD, will speak tomorrow at the Monte Jade Forum, an event organized by the Monte Jade Science and Technology Association (West Coast). The Forum is entitled Personalized Precision Medicine – What does it mean for the cancer patient? Dr. Tenenbaum will join oncologist Edmund Tai, MD, in a discussion of how personalized medicine, or “precision oncology,” can help cancer patients. Dr. Tenenbaum will discuss Cancer Commons as “an emerging patient-led movement that empowers each patient and their care team to get the best available knowledge for beating their cancer, and to update that knowledge in real time based on each patient’s outcome.”

The Forum takes place tomorrow, Nov 6, 2013, at 7:00pm at ITRI International in San Jose, CA. Registration is available online, and non-members can register for $20.

Listen: Marty Tenenbaum Featured in New Mendelspod Podcast

Cancer Commons founder Dr. Marty Tenenbaum is featured in a new podcast from Mendelspod. In the podcast, entitled “4 Reasons Clinical Trials Don’t Work,” Dr. Tenenbaum outlines the shortcomings of the current state of the clinical trial system, and offer solutions for improvement. Cancer Commons is key to his vision of a revamped cancer research system that focuses on individual cancer patients to find answers faster. Listen on the website, or download the podcast to listen later.